Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by DJDawgon Nov 06, 2023 1:39pm
426 Views
Post# 35719788

pre-BTD and BTD

pre-BTD and BTDFor those of you who were wondering what is the missing data for BTD application.

My hunch is that the main detail that makes BTD on hold at the moment is that FDA is wanting 18 m data vs current 15 m data.

Interesting fact (from my area of work) is that if you are doing a research trial and want to find out how patient is doing you are not allowed to just look up the chart or email the investigator or physician. If the protocol covered up to 15 m then you have to apply for approval to go and get more detail about how patients are doing.

The prevailing pattern of immune drugs is that they work (to a degree) while you are taking them and then once you stop, the cancer comes back for many, given a bit of time. From other companies I follow I get the sense that the FDA wants longer follow ups to make sure the CR is being held.

So, if TLT was told by FDA that the BTD needs 18 m data then they cannot submit BTD till they get the protocol modification approved and then they can call the research sites and get the 18m data.



<< Previous
Bullboard Posts
Next >>